Cannabis’ multifaceted nature cries out for a new breed of specialist, a cross between an economist and a botanist, self-trained to evaluate the economic firepower of a magical herb.
Anyone who’s poked around Cannabis Commerce knows we’re convinced that pursuing patient rights state-by-state is in a league of one as the single dumbest mistake committed in the long and storied history of American activism. If we’re dead-set against patient rights, then what exactly are we for?
Three years plus into pot’s tempestuous tenancy on Main Street, Denver can rightfully stake a claim as Planet Earth’s premier cannabiz incubator. Our man in the Mile High City watched the drama unfold.
“Winning” limited medical marijuana initiatives — as opposed to repealing prohibition — invites legislators into a vicious cycle of creating, editing, and deleting whatever proposition or referendum you voted for after the fact. That insures endless regulatory skirmishes until the end of days.
How much cannatax could be collected in a legal, regulated society? Lots, like $75 billion. And that’s just the USA’s share, in the the overground poteconomy’s infancy. Harvard’s enigmatic Dr. Jeffrey Miron, oft-quoted pot pontificator, greatly doubts it. Other poteconomists doubt him. Finally, the real lowdown.